New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
06:23 EDTBAYRYBayer extends offer for Algeta takeover offer
The Bayer Group is extending the offer period for the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo, by two days to February 26 at 09:00 CET. Except for the extension of the offer period, all other terms and conditions of the offer remain unchanged. Bayer is offering NOK 362 in cash per share for all issued Algeta shares. As of February 24 at 7:40 CET, Bayer had received acceptances and pre-acceptances of the offer for approximately 40,485,490 shares, representing approximately 92.17 % of Algeta's share capital in response to its voluntary takeover offer. The acceptance level is based on preliminary numbers and may be subject to adjustments. Currently, Bayer does not own any shares in Algeta ASA. All regulatory approvals required for completion of the proposed acquisition have been obtained. However, the offer is still subject to certain closing conditions, which are set out in the offer document published on January 20. These stipulate, among other things, that at least 90 % of Algeta's share capital must be tendered to Bayer. It remains to be verified by means of the final acceptance numbers that this condition is satisfied. Bayer maintains its right to further extend the offer period as set out in the offer document. Subject to the fulfillment or waiver of all offer conditions, Bayer expects to complete the acquisition in the first quarter of 2014.
News For BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
12:17 EDTBAYRYBayer, Cardinal Health sign contract manufacturing agreement for Xofigo
Subscribe for More Information
December 16, 2014
08:11 EDTBAYRYFoamix earns $2.5M milestone payment from Bayer
Subscribe for More Information
December 10, 2014
07:56 EDTBAYRYUBS to hold a conference
Agriculture Investor Day is being held in Chicago on December 10.
December 9, 2014
12:22 EDTBAYRYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:38 EDTBAYRYBayer downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
December 4, 2014
08:45 EDTBAYRYAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use